| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMTM8 |
| Uniprot No | Q8IZV2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-173aa |
| 氨基酸序列 | MEEPQRARSHTVTTTASSFAENFSTSSSSFAYDREFLRTLHGFLIVAEIVLGLLVWTLIAGTEYFRVPAFGWVMFVAVSYWVLTVFFLIIYITMTYTRIPQVPWTTVGLCFNGSAFVLYLSAAVVDASSVSPERDSHNFNSWAASSFFAFLVTICYAGNTYFSFIAWRSRTIQ |
| 分子量 | 44.77 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CMTM8蛋白的参考文献示例(内容为模拟概括，实际文献需通过学术数据库查询确认)：
1. **文献名称**: **"CMTM8 suppresses tumor cell migration via inhibition of EGFR/STAT3 signaling in breast cancer"**
**作者**: Zhang Y, et al.
**摘要**: 该研究发现重组人CMTM8蛋白通过抑制EGFR/STAT3信号通路，降低乳腺癌细胞的迁移和侵袭能力，提示CMTM8在肿瘤转移中可能具有抑制作用。
2. **文献名称**: **"Recombinant CMTM8 regulates PD-L1 expression and enhances antitumor immunity in lung adenocarcinoma"**
**作者**: Li H, et al.
**摘要**: 研究利用重组人CMTM8蛋白处理肺癌细胞，发现其通过下调PD-L1表达，增强T细胞介导的肿瘤细胞杀伤作用，为免疫治疗提供潜在靶点。
3. **文献名称**: **"Expression, purification and functional analysis of recombinant human CMTM8 in mammalian cells"**
**作者**: Wang X, et al.
**摘要**: 该文优化了重组人CMTM8蛋白在HEK293细胞中的表达和纯化流程，并证实其可抑制Hela细胞的增殖，为其后续功能研究奠定基础。
4. **文献名称**: **"CMTM8 as a tumor suppressor: Role in suppressing prostate cancer progression via modulating PI3K/AKT pathway"**
**作者**: Chen R, et al.
**摘要**: 通过体外实验发现，重组CMTM8蛋白能够抑制前列腺癌细胞PI3K/AKT信号通路的激活，进而诱导细胞凋亡并抑制肿瘤生长。
---
如需具体文献，建议通过 **PubMed (https://pubmed.ncbi.nlm.nih.gov)** 或 **Google Scholar** 检索关键词 "recombinant human CMTM8" 或结合研究领域(如肿瘤、免疫调控)获取最新进展。
CKLF-like MARVEL transmembrane domain-containing member 8 (CMTM8) is a member of the chemokine-like factor (CKLF) superfamily, characterized by a conserved MARVEL domain implicated in membrane-associated processes. This ubiquitously expressed protein plays multifaceted roles in immune regulation, tumor suppression, and cellular signaling. CMTM8 is located on human chromosome 3p22.3. a region frequently associated with tumor suppressor genes. Studies reveal its involvement in cancer progression, particularly in modulating EGFR, Wnt/β-catenin, and PD-L1 pathways. It inhibits tumor cell proliferation, migration, and metastasis in various cancers, including breast, lung, and prostate cancers, while promoting apoptosis. Additionally, CMTM8 regulates immune cell functions, such as B-cell activation and macrophage polarization, linking it to autoimmune diseases and infectious responses.
Recombinant human CMTM8 protein, produced via bacterial or mammalian expression systems, retains these functional properties. It serves as a critical tool for elucidating CMTM8’s molecular mechanisms, receptor interactions, and downstream signaling in vitro. Its therapeutic potential is under exploration, particularly in cancer immunotherapy and immune disorder treatments. Structural studies focus on its MARVEL domain, essential for membrane localization and protein-protein interactions. Despite progress, the full spectrum of its biological roles and clinical applications remains an active research area.
×
